References
- Expert Panel report 2: Guidelines for the diagnosis and management of asthma. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; May 1997. NIH publication No. 97–4051A
- Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid: Allen & Hanburys Limited UK Study Group. Lancet 1994; 344(8917): 219–24
- Curtiss PH, Clark WS, Herndon CH. Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. JAMA 1954; 156: 467–9
- Reid IR. Glucocorticoid osteoporosis—mechanisms and management. Eur J Endocrinol 1997; 137(3): 209–17
- MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104(5): 648–51
- Pouw EM, Prummel MF, Oosting H, et al. Beclomethasone inhalation decreases serum osteocalcin concentrations. BMJ 1991; 302(6777): 627–8
- Herrala J, Puolijoki H, Impivaara O, et al. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone 1994; 15(6): 621–3
- Boulet LP, Giguere MC, Milot J, et al. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 1994; 94(5): 796–803
- Ip M, Lam K, Yam L, et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994; 105(6): 1722–7
- McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(3 Pt 1): 704–9
- Thompson JM, Modin GW, Arnaud CD, et al. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int 1997; 61(5): 377–81
- Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125(12): 961–8
- Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7: 1063–9
- Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid- treated men. Arch Intern Med 1996; 156(11): 1173–7
- Diamond T, McGuigan L, Barbagallo S, et al. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995; 98(5): 459–63
- Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337(6): 382–7
- Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate therapy for the prevention and treatment of glucocorticoid- induced osteoporosis. N Engl J Med 1998; 339(5): 292–9
- Luengo M, Pons F, Martinez de Osaba MJ, et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994; 49(11): 1099–102
- Guaydier-Souquieres G, Kotzki PO, Sabatier JP, et al. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double- masked randomized study. Osteoporos Int 1996; 6(2): 171–7
- Lems WF, Jacobs JW, Bijlsma JW, et al. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 1997; 56(6): 357–63
- Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7